Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

Author： Alva Ajjai  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 749-757

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3923-3931

Blackwell Publishing

Access to resources Recommend Favorite

A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer

By Beardsley Emma  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1652-1659

Springer Publishing Company

Access to resources Recommend Favorite

Sipuleucel-T: In Metastatic Castration-Resistant Prostate Cancer

By Plosker Greg L.  

Drugs, Vol. 71, Iss. 1, 2011-01 ,pp. : 101-108

Adis International

Access to resources Recommend Favorite

Abiraterone Acetate: In Metastatic Castration-Resistant Prostate Cancer

By Yang Lily P.H.  

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 2067-2077

Adis International

Access to resources Recommend Favorite

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

By Schelman William   Liu Glenn   Wilding George   Morris Thomas   Phung De   Dreicer Robert  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 118-125

Springer Publishing Company

Access to resources Recommend Favorite